sodium deoxyribonucleate
Trade name: Derinat
Small moleculeapproved
Approved
Apr 1, 1964
Clinical trial activity
2 trials · 2 clinical orgs · 2 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started May 1, 2010 (NCT02115984)
Timeline
Indications
Approved for
Mechanism of action
- Staphylococcus aureusBLOCKER
Staphylococcus aureus blocker
Combination products
elase-chloromycetin
Approval history
- approvedApr 1, 1964
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- sodium deoxyribonucleate
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04149431 | Phase 3 | Dec 15, 2019 | PharmPak, LLC |
| NCT02115984 | Phase 2 | May 1, 2010 | Panagen, Limited Liability Company |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Panagen, Limited Liability Company | For profit | 1 | 1 | 1 | 2010 |
| PharmPak, LLC | For profit | 1 | 1 | 1 | 2019 |
2 organizations
Page 1 / 1
Marketing (3)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Parke-Davis | For profit | NDA2 | Apr 1, 1964 |
| Pfizer | For profit | NDA2 | Apr 1, 1964 |
| Pfizer | For profit | NDA | Apr 1, 1964 |